RecruitingNot Applicable

Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.

Switzerland225 participantsStarted 2025-09-10

Plain-language summary

Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consented for cardiopulmonary bypass surgery for cardiac reason * Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language Exclusion Criteria: * Know genetic life limiting conditions * Syndrome patients who are scheduled or highly likely to be operated on more than one organ * Body weight at time of surgery less than 2.5 kg * Being recruited and enrolled for an interventional study protocol

What they're measuring

Surrogates of Heart Failure

Timeframe: 1 year post surgery

Trial details

NCT IDNCT07029230

SponsorMartin Schweiger

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Martin Schweiger, Prof, MD, MBA

+41 44 249 6511 sst2@kispi.uzh.ch

View on ClinicalTrials.gov More Congenital Heart Surgery trials